University of Leicester
Browse
Commentary for Lancet FINAL.pdf (258.56 kB)

Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction

Download (258.56 kB)
journal contribution
posted on 2019-03-15, 10:40 authored by A Sharp, C Cornforth, R Jackson, J Harrold, MA Turner, L Kenny, PN Baker, ED Johnstone, A Khalil, P von Dadelszen, AT Papageorghiou, Z Alfirevic
Severe early-onset fetal growth restriction (FGR) is an untreatable condition associated with significant mortality and morbidity for the fetus and neonate. There has been growing interest in novel therapies such as nitic oxide donors/promotors to improve placental function and outcomes for these high-risk pregnancies. The recently published STRIDER UK trial was designed to test the effectiveness of sildenafil (25mg three times a day) versus placebo at prolonging gestation in severe early-onset.

History

Citation

The Lancet Child & Adolescent Health, 2019, 3 (3) pp. e2-e3

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES

Version

  • AM (Accepted Manuscript)

Published in

The Lancet Child & Adolescent Health

Publisher

Elsevier: Lancet

eissn

2352-4642

Acceptance date

2019-01-14

Copyright date

2019

Available date

2019-07-29

Publisher version

https://www.sciencedirect.com/science/article/pii/S2352464219300203?via=ihub

Notes

The file associated with this record is under embargo until 6 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    Keywords

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC